EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Brii Biosciences's Enterprise Value is HK$-2,034.97 Mil.
Brii Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-649.72 Mil. Therefore, Brii Biosciences's EV-to-FCF for today is 3.13.
The historical rank and industry rank for Brii Biosciences's EV-to-FCF or its related term are showing as below:
HKSE:02137'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.99 Med: 1.9 Max: 3.26
Current: 3.17
During the past 5 years, the highest EV-to-FCF of Brii Biosciences was 3.26. The lowest was -8.99. And the median was 1.90.
HKSE:02137's EV-to-FCF is ranked better than 56.99% of 379
companies
in the Biotechnology industry
Industry Median: 8.31
vs HKSE:02137: 3.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Brii Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Brii Biosciences's EV-to-FCF
For the Biotechnology subindustry, Brii Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's EV-to-FCF falls into.
Brii Biosciences's current Enterprise Value is HK$-2,034.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-649.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Brii Biosciences's PE Ratio for today is calculated as:
Brii Biosciences's share price for today is HK$1.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.262.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Brii Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Brii Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Brii Biosciences (HKSE:02137) Business Description
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02137 has been successfully added to your 